-
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. J Immunother Cancer. 2026 Feb 11; 14(2). Chae YK, Othus M, Patel SP, Backes FJ, O'Malley DM, Cristea M, Naing A, Kurnit K, Eskander RN, T Goodrich S, Robinson WR, Scalici J, Chan J, Ali-Ahmad H, Hays J, McCormick C, Kim EJ, Sueblinvong T, Ahmed A, Siedel J, Thomes Pepin J, Bottsford-Miller JN, Fagbemi SO, Jaslowski AJ, Kim HS, Chung LI, Moloney-Lineen C, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. PMID: 41672597; PMCID: PMC12911695.
-
Divergent oncogenic signaling and immune microenvironment changes in low-grade serous ovarian cancer patients undergoing intraperitoneal chemotherapy. NPJ Precis Oncol. 2025 Dec 14; 10(1):1. Bishara I, Cosgrove PA, Majumdar S, Egelston CA, Flores OC, Nakamura B, Ruel N, Frankel PH, Yost SE, Chang S, Jung A, Cristea M, Raoof M, Bild AH, Nath A, Dellinger TH. PMID: 41392193; PMCID: PMC12764849.
-
PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies. Biomedicines. 2025 May 06; 13(5). Apelian S, Martincuks A, Whittum M, Yasukawa M, Nguy L, Mathyk B, Andikyan V, Anderson ML, Rutherford T, Cristea M, Stewart D, Kohut A. PMID: 40426953; PMCID: PMC12108591.
-
Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial. Front Oncol. 2024; 14:1404936. Nakamura B, Senguttuvan R, Ruel NH, Frankel PH, Yost SE, Cole S, Chang S, Jung A, Eng M, Tinsley R, Stewart D, Wang E, Cohen J, Villella J, Whelan RL, Merchea A, DePeralta DK, Cristea M, Wakabayashi MT, Raoof M, Dellinger TH. PMID: 39148906; PMCID: PMC11324501.
-
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib. Gynecol Oncol. 2024 08; 187:105-112. Liu JF, Xiong N, Wenham RM, Wahner-Hendrickson A, Armstrong DK, Chan N, O'Malley DM, Lee JM, Penson RT, Cristea MC, Abbruzzese JL, Matsuo K, Olawaiye AB, Barry WT, Cheng SC, Polak M, Swisher EM, Shapiro GI, Kohn EC, Ivy SP, Matulonis UA. PMID: 38759516; PMCID: PMC11309890.
-
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer. Gynecol Oncol. 2024 03; 182:124-131. Cristea MC, Stewart D, Synold T, Ruel N, Mortimer J, Wang E, Jung A, Wilczynski S, Konecny GE, Eng M, Kilpatrick L, Han E, Dellinger T, Hakim A, Lee S, Morgan RJ, Wakabayashi MT, Frankel PH. PMID: 38262235.
-
Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer. Cancer Res Commun. 2023 12 20; 3(12):2585-2595. Kos FJ, Frankel P, Cristea M, Eng M, Tinsley R, Dempsey S, Ruel N, Stewart D, Dellinger TH, Diamond DJ. PMID: 38032111; PMCID: PMC10732002.
-
Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer. Ann Surg Oncol. 2023 Dec; 30(13):8144-8155. Senguttuvan RN, Santiago NL, Han ES, Lee B, Lee S, Lin WC, Kebria M, Hakim A, Lin JF, Wakabayashi MT, Ruel N, Tinsley R, Eng M, Stewart DB, Wang EW, Paz BI, Wu X, Cho H, Liang WS, Rodriguez-Rodriguez L, Cristea MC, Raoof M, Dellinger TH. PMID: 37710139; PMCID: PMC10625947.
-
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nat Commun. 2023 08 07; 14(1):4737. Lee EHJ, Murad JP, Christian L, Gibson J, Yamaguchi Y, Cullen C, Gumber D, Park AK, Young C, Monroy I, Yang J, Stern LA, Adkins LN, Dhapola G, Gittins B, Chang WC, Martinez C, Woo Y, Cristea M, Rodriguez-Rodriguez L, Ishihara J, Lee JK, Forman SJ, Wang LD, Priceman SJ. PMID: 37550294; PMCID: PMC10406808.
-
Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer. J Ovarian Res. 2023 Jul 17; 16(1):141. Adamson AW, Ding YC, Steele L, Leong LA, Morgan R, Wakabayashi MT, Han ES, Dellinger TH, Lin PS, Hakim AA, Wilczynski S, Warden CD, Tao S, Bedell V, Cristea MC, Neuhausen SL. PMID: 37460928; PMCID: PMC10351177.
-
BRCA germline mutations in multiethnic gynecologic patients: A 10-year retrospective analysis from a single cancer institute. PLoS One. 2023; 18(6):e0286998. Wei CH, Shehayeb S, Santiago NL, Kruper L, Han E, Wang E, Cristea M, Rodriguez-Rodriguez L, Yost SE, Stewart D. PMID: 37310942; PMCID: PMC10263324.
-
Genomic Analyses of Germline and Somatic Variation in High-Grade Serous Ovarian Cancer. Res Sq. 2023 Feb 20. Adamson AW, Ding YC, Steele L, Leong LA, Morgan R, Wakabayashi MT, Han ES, Dellinger TH, Lin PS, Hakim AA, Wilczynski S, Warden CD, Tao S, Bedell V, Cristea MC, Neuhausen SL. PMID: 36865331; PMCID: PMC9980206.
-
Care Processes and Quality-of-Life Outcomes Affecting the Gynecologic Cancer Survivorship Experience. Oncol Nurs Forum. 2023 02 17; 50(2):185-200. Reb AM, Economou D, Cope DG, Borneman T, Tejada MS, Han ES, Cristea M, Ferrell BR. PMID: 37677803.
-
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. bioRxiv. 2023 Jan 07. Jun Lee EH, Cullen C, Murad JP, Gumber D, Park AK, Yang J, Stern LA, Adkins LN, Dhapola G, Gittins B, Chung-Chang W, Martinez C, Woo Y, Cristea M, Rodriguez-Rodriguez L, Ishihara J, Lee JK, Forman SJ, Wang LD, Priceman SJ. PMID: 36711615; PMCID: PMC9881930.
-
Leveraging an Informatics Approach to Identify an Unmet Clinical Need for BRCA1/2 Testing Among Patients With Ovarian Cancer. JCO Clin Cancer Inform. 2022 09; 6:e2200034. Gray SW, Ottesen RA, Currey M, Cristea M, Nikowitz J, Shehayeb S, Lozano V, Hom J, Kilburn J, Lopez LN, Wing S, Sosa E, Shen J, Morris M, Dilsizian B, Joseph T, Shen J, Adeimy C, Phillips T, Bahadini B, Niland JC. PMID: 36049148; PMCID: PMC9470148.
-
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022 09; 20(9):972-980. Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. PMID: 36075393.
-
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial. Cancers (Basel). 2022 Aug 23; 14(17). Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, Ünsal-Kaçmaz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, Diamond JR. PMID: 36077617; PMCID: PMC9454848.
-
Family Caregiver Preparedness: Developing an Educational Intervention for Symptom Management. Clin J Oncol Nurs. 2022 04 01; 26(2):165-175. Ferrell BR, Ruel N, Borneman T, Koczywas M, Cristea M. PMID: 35302549.
-
Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer. JCO Precis Oncol. 2022 03; 6:e2100239. Dellinger TH, Han ES, Raoof M, Lee B, Wu X, Cho H, He TF, Lee P, Razavi M, Liang WS, Schmolze D, Priceman SJ, Lee S, Lin WC, Lin JF, Kebria M, Hakim A, Ruel N, Stewart DB, Wang EW, Paz BI, Wakabayashi MT, Cristea MC, Rodriguez-Rodriguez L. PMID: 35357903; PMCID: PMC8984280.
-
PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer. Front Oncol. 2021; 11:724104. Martincuks A, Song J, Kohut A, Zhang C, Li YJ, Zhao Q, Mak E, Rodriguez-Rodriguez L, Yu H, Cristea M. PMID: 34956861; PMCID: PMC8693573.
-
Characterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging? Gynecol Oncol. 2022 01; 164(1):39-45. Ladbury C, Li R, Shiao J, Liu J, Cristea M, Han E, Dellinger T, Lee S, Wang E, Fisher C, Chen YJ, Amini A, Robin T, Glaser S. PMID: 34794840.
-
Recall of Genomic Testing Results Among Patients with Cancer. Oncologist. 2021 12; 26(12):e2302-e2305. Wing SE, Hu H, Lopez L, Solomon I, Shen J, Raquel C, Sur M, Chao J, Cristea M, Fakih M, Mortimer J, Pal S, Reckamp K, Yuan Y, Gray SW. PMID: 34355454; PMCID: PMC8649013.
-
PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial. Ann Surg Oncol. 2022 Jan; 29(1):175-185. Raoof M, Malhotra G, Kohut A, O'Leary M, Frankel P, Tran T, Fakih M, Chao J, Lim D, Woo Y, Paz IB, Lew M, Cristea MC, Rodriguez-Rodriguez L, Fong Y, Blakely A, Whelan R, Reymond MA, Merchea A, Dellinger TH. PMID: 34387765.
-
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers (Basel). 2021 Jun 03; 13(11). Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Chao J, Chen C, Nasser MW, Chirravuri-Venkata R, Jain M, Smith L, Yost SE, Reckamp KL, Pillai R, Arvanitis L, Afkhami M, Wang EW, Chung V, Cristea M, Fakih M, Koczywas M, Massarelli E, Mortimer J, Yuan Y, Batra SK, Pal S, Salgia R. PMID: 34204917; PMCID: PMC8199748.
-
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun. 2021 05 24; 12(1):3039. Nath A, Cosgrove PA, Mirsafian H, Christie EL, Pflieger L, Copeland B, Majumdar S, Cristea MC, Han ES, Lee SJ, Wang EW, Fereday S, Traficante N, Salgia R, Werner T, Cohen AL, Moos P, Chang JT, Bowtell DDL, Bild AH. PMID: 34031395; PMCID: PMC8144406.
-
Germline mutations and age at onset of lung adenocarcinoma. Cancer. 2021 08 01; 127(15):2801-2806. Reckamp KL, Behrendt CE, Slavin TP, Gray SW, Castillo DK, Koczywas M, Cristea MC, Babski KM, Stearns D, Marcum CA, Rodriguez YP, Hass AJ, Vecchio MM, Mora P, Cervantes AE, Sand SR, Mejia RM, Tsou TC, Salgia R, Weitzel JN. PMID: 33858029; PMCID: PMC8794435.
-
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). Clin Lung Cancer. 2021 07; 22(4):313-323.e1. Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, Redman MW, Kelly K, Gandara DR. PMID: 33745865; PMCID: PMC8562492.
-
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 02 02; 19(2):191-226. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM. PMID: 33545690.
-
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 01 23; 397(10271):281-292. Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, Fleming GF, Welch S, Dhani NC, Stockley T, Rath P, Karakasis K, Jones GN, Jenkins S, Rodriguez-Canales J, Tracy M, Tan Q, Bowering V, Udagani S, Wang L, Kunos CA, Chen E, Pugh TJ, Oza AM. PMID: 33485453; PMCID: PMC10792546.
-
A nurse-led intervention for fear of cancer progression in advanced cancer: A pilot feasibility study. Eur J Oncol Nurs. 2020 Dec; 49:101855. Reb AM, Borneman T, Economou D, Cangin MA, Cope DG, Ma H, Ruel N, Sharpe L, Patel SK, Cristea M, Koczywas M, Ferrell B. PMID: 33120211; PMCID: PMC8493814.
-
Frontline Management of Epithelial Ovarian Cancer-Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research. J Clin Med. 2020 Sep 01; 9(9). Wang EW, Wei CH, Liu S, Lee SJ, Shehayeb S, Glaser S, Li R, Saadat S, Shen J, Dellinger T, Han ES, Stewart D, Wilczynski S, Cristea M, Rodriguez-Rodriguez L. PMID: 32882942; PMCID: PMC7565288.
-
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645. Hamilton E, O'Malley DM, O'Cearbhaill R, Cristea M, Fleming GF, Tariq B, Fong A, French D, Rossi M, Brickman D, Moore K. PMID: 32513564; PMCID: PMC8227801.
-
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020 05; 85(5):979-993. Coyne GO', Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, Nieva JJ, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE, Kinders RJ, Piekarz RL, Kummar S, Chen AP, Doroshow JH. PMID: 32314030; PMCID: PMC7188725.
-
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clin Cancer Res. 2020 06 01; 26(11):2477-2486. Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, Matei D, Jimenez W, Johnston C, Cristea M, Tonkin K, Ghatage P, Lheureux S, Mehta A, Quintos J, Tan Q, Kamel-Reid S, Ludkovski O, Tsao MS, Wright JJ, Oza AM. PMID: 31992589; PMCID: PMC7269808.
-
Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies. Cancer Biother Radiopharm. 2020 Feb; 35(1):10-15. Akhavan D, Yazaki P, Yamauchi D, Simpson J, Frankel PH, Bading J, Colcher D, Poku K, Chen YJ, Lim D, Cristea M, Wu A, Shively J, Wong JYC. PMID: 31910346; PMCID: PMC7044770.
-
Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Cancer Chemother Pharmacol. 2019 12; 84(6):1201-1208. Luu T, Frankel P, Beumer JH, Lim D, Cristea M, Appleman LJ, Lenz HJ, Gandara DR, Kiesel BF, Piekarz RL, Newman EM. PMID: 31522242; PMCID: PMC6821594.
-
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw. 2019 08 01; 17(8):896-909. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. PMID: 31390583.
-
Role of Locoregional Treatment in Vulvar Cancer With Pelvic Lymph Node Metastases: Time to Reconsider FIGO Staging? J Natl Compr Canc Netw. 2019 08 01; 17(8):922-930. Shinde A, Li R, Amini A, Chen YJ, Cristea M, Wang W, Wakabyashi M, Han E, Yashar C, Albuquerque K, Beriwal S, Glaser S. PMID: 31390593.
-
Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer Treat Res Commun. 2019; 21:100155. Gupta R, Cristea M, Frankel P, Ruel C, Chen C, Wang Y, Morgan R, Leong L, Chow W, Koczywas M, Koehler S, Lim D, Luu T, Martel C, McNamara M, Somlo G, Twardowski P, Yen Y, Idorenyi A, Raechelle T, Carroll M, Chung V. PMID: 31279962; PMCID: PMC9018111.
-
Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. Target Oncol. 2019 06; 14(3):269-283. Pan K, Gong J, Huynh K, Cristea M. PMID: 31069647.
-
Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer. J Cancer Res Ther Oncol. 2019 Mar; 7(1). Hill A, Cristea M, He M, Frankel P, Neuhausen S, Pal SK, Jones JO. PMID: 34926721; PMCID: PMC8682960.
-
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 05; 20(5):636-648. Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. PMID: 30948273.
-
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303). Front Oncol. 2019; 9:132. Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN. PMID: 30915273; PMCID: PMC6421302.
-
Antibody-drug conjugates for ovarian cancer: current clinical development. Curr Opin Obstet Gynecol. 2019 02; 31(1):18-23. Stewart D, Cristea M. PMID: 30531606.
-
A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemother Pharmacol. 2019 03; 83(3):589-598. Cristea MC, Frankel P, Synold T, Rivkin S, Lim D, Chung V, Chao J, Wakabayashi M, Paz B, Han E, Lin P, Leong L, Hakim A, Carroll M, Prakash N, Dellinger T, Park M, Morgan RJ. PMID: 30623229; PMCID: PMC8919712.
-
Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Front Immunol. 2018; 9:2268. Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ. PMID: 30510550; PMCID: PMC6254427.
-
Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology. Gynecol Oncol. 2018 10; 151(1):82-90. Shinde A, Li R, Amini A, Chen YJ, Cristea M, Dellinger T, Wang W, Wakabayashi M, Beriwal S, Glaser S. PMID: 30170976.
-
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 10; 82(4):723-732. Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM. PMID: 30128950; PMCID: PMC6342617.
-
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. JAMA Oncol. 2018 07 12; 4(7):e173776. Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, Fleming GF, Tinker AV, Hirte HW, Tsoref D, Mackay H, Dhani NC, Ghatage P, Weberpals J, Welch S, Pham NA, Motta V, Sotov V, Wang L, Karakasis K, Udagani S, Kamel-Reid S, Streicher HZ, Shaw P, Oza AM. PMID: 29145543; PMCID: PMC6145732.
-
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 03; 148(3):507-514. Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP. PMID: 29352572.
-
p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clin Cancer Res. 2018 03 15; 24(6):1315-1325. Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, Kaltcheva T, Leong L, Morgan R, Chung V, Tinsley R, Eng M, Wilczynski S, Ellenhorn JDI, Diamond DJ, Cristea M. PMID: 29301826; PMCID: PMC5856606.
-
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 11 10; 34(32):3854-3863. Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. PMID: 27601552; PMCID: PMC5477982.
-
Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1427-1433. Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA. PMID: 27442965; PMCID: PMC5106306.
-
The impact of lung cancer surgery on quality of life trajectories in patients and family caregivers. Lung Cancer. 2016 11; 101:35-39. Kim JY, Sun V, Raz DJ, Williams AC, Fujinami R, Reckamp K, Koczywas M, Cristea M, Hurria A, Ferrell B. PMID: 27794406; PMCID: PMC5123701.
-
New Approaches for Immune Directed Treatment for Ovarian Cancer. Curr Treat Options Oncol. 2016 Mar; 17(3):14. Hardwick N, Frankel PH, Cristea M. PMID: 26942589.
-
Long-Term Effect of an Interdisciplinary Supportive Care Intervention for Lung Cancer Survivors After Surgical Procedures. Ann Thorac Surg. 2016 Feb; 101(2):495-502; discussion 502-3. Raz DJ, Sun V, Kim JY, Williams AC, Koczywas M, Cristea M, Reckamp K, Hayter J, Tiep B, Ferrell B. PMID: 26443881; PMCID: PMC4718894.
-
Interdisciplinary Palliative Care for Patients With Lung Cancer. J Pain Symptom Manage. 2015 Dec; 50(6):758-67. Ferrell B, Sun V, Hurria A, Cristea M, Raz DJ, Kim JY, Reckamp K, Williams AC, Borneman T, Uman G, Koczywas M. PMID: 26296261; PMCID: PMC4666729.
-
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10; 33(26):2841-7. Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. PMID: 26240233; PMCID: PMC4554746.
-
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer. 2015 Sep 15; 121(18):3298-306. Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett SM. PMID: 26033830; PMCID: PMC4864011.
-
Overcoming immunosuppression to enhance a p53MVA vaccine. Oncoimmunology. 2014 Nov; 3(10):e958949. Hardwick N, Chung V, Cristea M, Ellenhorn JD, Diamond DJ. PMID: 25941580; PMCID: PMC4292557.
-
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 09; 111(12):2268-74. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. PMID: 25349975; PMCID: PMC4264453.
-
Death awareness, feelings of uncertainty, and hope in advanced lung cancer patients: can they coexist? Int J Palliat Nurs. 2014 Jun; 20(6):271-7. Borneman T, Irish T, Sidhu R, Koczywas M, Cristea M. PMID: 25040862.
-
Interdisciplinary palliative care intervention in metastatic non-small-cell lung cancer. Clin Lung Cancer. 2013 Nov; 14(6):736-44. Koczywas M, Cristea M, Thomas J, McCarty C, Borneman T, Del Ferraro C, Sun V, Uman G, Ferrell B. PMID: 23871439; PMCID: PMC3818339.
-
A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer. 2013 Jan 15; 13:20. Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, Felder M, Stewart S, Harter J, Henslee-Downey J, Kramer D, Neugebauer R, Stupp R. PMID: 23320927; PMCID: PMC3600662.
-
Longitudinal changes in function, symptom burden, and quality of life in patients with early-stage lung cancer. Ann Surg Oncol. 2013 Jun; 20(6):1788-97. Koczywas M, Williams AC, Cristea M, Reckamp K, Grannis FW, Tiep BL, Uman G, Ferrell B. PMID: 23143593; PMCID: PMC3657328.
-
Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet. 2012 Jan-Feb; 205(1-2):34-41. Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN. PMID: 22429596; PMCID: PMC3337330.
-
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 2012 Oct 18; 31(42):4559-66. Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. PMID: 22139083; PMCID: PMC3342446.
-
Osteonecrosis of the humeral head in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol. 2011 Nov; 6(11):1960-1. Koczywas M, Cristea MC. PMID: 22005475.
-
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Feb; 69(2):505-14. Portnow J, Frankel P, Koehler S, Twardowski P, Shibata S, Martel C, Morgan R, Cristea M, Chow W, Lim D, Chung V, Reckamp K, Leong L, Synold TW. PMID: 21850464; PMCID: PMC3506384.
-
Quality of life and barriers to symptom management in colon cancer. Eur J Oncol Nurs. 2012 Jul; 16(3):276-80. Sun V, Borneman T, Koczywas M, Cristea M, Piper BF, Uman G, Ferrell B. PMID: 21783415; PMCID: PMC3223329.
-
Predictors of finding benefit after lung cancer diagnosis. Psychooncology. 2012 Apr; 21(4):365-73. Thornton AA, Owen JE, Kernstine K, Koczywas M, Grannis F, Cristea M, Reckamp K, Stanton AL. PMID: 21254308.
-
Targeted agents in ovarian cancer. Womens Health (Lond). 2010 Sep; 6(5):679-94. Kristedja TS, Morgan RJ, Cristea M. PMID: 20887168.
-
Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol. 2010 May; 2(3):175-87. Cristea M, Han E, Salmon L, Morgan RJ. PMID: 21789133; PMCID: PMC3126016.
-
Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. Anticancer Res. 2010 Jan; 30(1):167-74. Luu T, Chow W, Lim D, Koczywas M, Frankel P, Cristea M, Margolin K, Doroshow JH, Somlo G, Gaur S, Yen Y, Morgan RJ. PMID: 20150632.
-
Occult primary. J Natl Compr Canc Netw. 2008 Nov; 6(10):1026-60. Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. PMID: 19176200.
-
An interdisciplinary care approach for integration of palliative care in lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):352-60. Borneman T, Koczywas M, Cristea M, Reckamp K, Sun V, Ferrell B. PMID: 19073518.
-
Left atrial mass. J Thorac Oncol. 2008 Apr; 3(4):427. Cristea MC, Venkataraman K. PMID: 18379364.
-
[Some epidemiological indicators in bronchopulmonary cancer in Sector 5 of Bucharest (study of 525 cases)]. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol. 1975 Apr-Jun; 24(2):85-92. Cristea M, Morgenstern H, Voicu Tr, Mangiulea V, Pruteanu L, Popovici O, Matei M. PMID: 171736.
US